Quantum BioPharma Gets FDA Nod for Groundbreaking MS Trial
Quantum BioPharma receives FDA clearance for Phase 2 trial of Lucid-MS, a first-in-class myelin repair therapy for progressive MS. A potential game-changer.
This news matters because it signals a potential breakthrough in multiple sclerosis treatment, moving beyond symptom management to actual myelin repair. For the millions living with MS, Lucid-MS offers hope for halting disease progression and restoring lost function. If successful, it could transform the standard of care and open a new frontier in regenerative neurology, impacting patients, investors, and the pharmaceutical industry at large.
